Noriyuki Kasahara Selected Research

Flucytosine (Ancobon)

2/2020	Efficient Prodrug Activator Gene Therapy by Retroviral Replicating Vectors Prolongs Survival in an Immune-Competent Intracerebral Glioma Model.
3/2018	A Retroviral Replicating Vector Encoding Cytosine Deaminase and 5-FC Induces Immune Memory in Metastatic Colorectal Cancer Models.
1/2018	Therapeutic activity of retroviral replicating vector-mediated prodrug activator gene therapy for pancreatic cancer.
7/2017	Toca 511 gene transfer and treatment with the prodrug, 5-fluorocytosine, promotes durable antitumor immunity in a mouse glioma model.
7/2017	Retroviral replicating vector-mediated gene therapy achieves long-term control of tumor recurrence and leads to durable anticancer immunity.
1/2016	Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma.
2/2015	Intravenous administration of retroviral replicating vector, Toca 511, demonstrates therapeutic efficacy in orthotopic immune-competent mouse glioma model.
10/2014	Radiosensitization of gliomas by intracellular generation of 5-fluorouracil potentiates prodrug activator gene therapy with a retroviral replicating vector.
8/2013	Combined alloreactive CTL cellular therapy with prodrug activator gene therapy in a model of breast cancer metastatic to the brain.
2/2012	Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Noriyuki Kasahara Research Topics

Disease

45	Neoplasms (Cancer) 03/2021 - 05/2002
18	Glioma (Gliomas) 01/2021 - 01/2003
7	Glioblastoma (Glioblastoma Multiforme) 03/2021 - 12/2005
6	Brain Neoplasms (Brain Tumor) 01/2021 - 02/2012
6	Infections 04/2016 - 12/2005
3	Neoplasm Metastasis (Metastasis) 01/2019 - 06/2007
3	Adenocarcinoma 01/2018 - 05/2002
3	Malignant Mesothelioma 08/2015 - 08/2010
3	Vesicular Stomatitis 05/2010 - 05/2004
2	Colorectal Neoplasms (Colorectal Cancer) 03/2018 - 06/2007
2	Pancreatic Neoplasms (Pancreatic Cancer) 01/2018 - 02/2012
2	Carcinogenesis 01/2014 - 02/2012
2	Prostatic Neoplasms (Prostate Cancer) 12/2013 - 01/2009
2	Melanoma (Melanoma, Malignant) 07/2007 - 05/2007
2	Epidermolysis Bullosa Dystrophica (Dystrophic Epidermolysis Bullosa) 08/2004 - 12/2002
1	Hepatocellular Carcinoma (Hepatoma) 01/2019
1	Osteosarcoma (Osteogenic Sarcoma) 01/2019
1	Medulloblastoma 01/2019
1	Virus Diseases (Viral Diseases) 08/2015
1	Leukemia 08/2015
1	Head and Neck Neoplasms (Head and Neck Cancer) 12/2014
1	Colitis 04/2014
1	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 04/2014
1	Liver Neoplasms (Liver Cancer) 01/2014
1	Liver Cirrhosis (Hepatic Cirrhosis) 01/2014
1	Retinoblastoma (Glioblastoma, Retinal) 01/2014
1	Needlestick Injuries (Needlestick Injury) 01/2014

Drug/Important Bio-Agent (IBA)

19	ProdrugsIBA 01/2021 - 01/2003
15	Cytosine DeaminaseIBA 02/2020 - 01/2003
14	Flucytosine (Ancobon)FDA Link 02/2020 - 01/2003
12	vocimagene amiretrorepvecIBA 01/2021 - 01/2012
9	Fluorouracil (Carac)FDA LinkGeneric 03/2018 - 06/2007
6	Green Fluorescent ProteinsIBA 01/2019 - 03/2004
5	Pharmaceutical PreparationsIBA 01/2019 - 01/2012
5	Proteins (Proteins, Gene)FDA Link 04/2016 - 04/2004
4	CytokinesIBA 01/2016 - 01/2009
4	AntigensIBA 08/2015 - 05/2002
3	Therapeutic UsesIBA 08/2017 - 03/2004
2	Messenger RNA (mRNA)IBA 01/2016 - 01/2014
2	Interleukin-6 (Interleukin 6)IBA 01/2016 - 04/2014
2	EndostatinsIBA 08/2015 - 03/2004
2	EnzymesIBA 02/2015 - 03/2004
2	VaccinesIBA 01/2015 - 07/2007
2	Firefly LuciferasesIBA 04/2014 - 06/2007
2	RNA (Ribonucleic Acid)IBA 01/2014 - 06/2013
2	MidkineIBA 11/2013 - 08/2010
2	LuciferasesIBA 08/2010 - 01/2009
2	Glycoproteins (Glycoprotein)IBA 05/2010 - 05/2004
1	tretazicarIBA 02/2020
1	4- (N- methyl- N- (4- (trifluoromethyl)phenyl)sulfamoyl) benzoic acidIBA 01/2019
1	HhAntag691IBA 01/2019
1	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 01/2018
1	Immunoglobulin G (IgG)IBA 08/2017
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 08/2017
1	Neoplasm Antigens (Tumor Antigens)IBA 07/2017
1	ChemokinesIBA 01/2016
1	InterferonsIBA 01/2016
1	Interleukin-8 (Interleukin 8)IBA 01/2016
1	AngiostatinsIBA 08/2015
1	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 08/2015
1	Internal Ribosome Entry SitesIBA 08/2015
1	enhanced green fluorescent proteinIBA 08/2015
1	AsbestosIBA 08/2015
1	Toll-Like Receptor 4IBA 08/2015
1	Polytetrafluoroethylene (Teflon)FDA Link 02/2015
1	Extracellular Matrix ProteinsIBA 02/2015
1	Stainless Steel (Steel, Stainless)IBA 02/2015
1	Interleukin-2 (IL2)IBA 01/2015
1	Cisplatin (Platino)FDA LinkGeneric 12/2014
1	Delayed-Action PreparationsIBA 10/2014
1	Antiviral Agents (Antivirals)IBA 08/2014
1	Antineoplastic Agents (Antineoplastics)IBA 08/2014
1	src-Family KinasesIBA 05/2014
1	Focal Adhesion Protein-Tyrosine KinasesIBA 05/2014
1	IntegrinsIBA 05/2014
1	Indicators and Reagents (Reagents)IBA 05/2014
1	Dextrans (Dextran)FDA Link 04/2014
1	sodium sulfate (sodium bisulfate)FDA LinkGeneric 04/2014
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 04/2014
1	Ethanol (Ethyl Alcohol)IBA 04/2014
1	Dextran SulfateIBA 04/2014
1	Interleukin-10 (Interleukin 10)IBA 04/2014
1	CyclinsIBA 01/2014
1	OligonucleotidesIBA 01/2014
1	gadoteridol (Prohance)FDA Link 01/2014
1	AlbuminsIBA 01/2014
1	Serum AlbuminIBA 01/2014
1	Contrast MediaIBA 01/2014
1	Hemostatics (Antihemorrhagics)IBA 01/2014
1	Bone Morphogenetic Proteins (Bone Morphogenetic Protein)IBA 12/2013
1	adenovirus receptorIBA 11/2013

Therapy/Procedure

9	Therapeutics 03/2021 - 11/2005
6	Immunotherapy 03/2021 - 06/2007
4	Oncolytic Virotherapy 11/2013 - 12/2005
3	Radiotherapy 10/2020 - 05/2014
2	Injections 01/2018 - 01/2014
1	Drug Therapy (Chemotherapy) 10/2020
1	Intravenous Administration 02/2015
1	Enema (Enemas) 04/2014
1	Intravenous Injections 01/2014